Tokyo giant to acquire England's Arakis

Sosei will buy Cambridge, UK-based biopharma Arakis -- a 2005 Fierce 15 winner -- for £106.5 million, the companies announced. The buyout comes on the heels of Novartis' decision to develop one of Arakis' products into a treatment for smoker's cough. Arakis has three other products in clinical development, including a cancer pain drug that will enter Phase III trials later this year.

- read this Business Weekly story for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.